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correlate with immune recovery but not
mitochondrial dysfunction in HIV infection
Brendan AI Payne1,2*, David Ashley Price2 and Patrick F Chinnery1Abstract
Background: Anti-retroviral treated HIV-infected patients are at risk of mitochondrial toxicity, but non-invasive
markers are lacking. Serum FGF-21 (fibroblast growth factor 21) levels correlate strongly with muscle biopsy findings
in inherited mitochondrial disorders. We therefore aimed to determine whether serum FGF-21 levels correlate with
muscle mitochondrial dysfunction in HIV-infected patients.
Findings: We performed a cross-sectional study of anti-retroviral treated HIV-infected subjects (aged 29 – 71 years,
n = 32). Serum FGF-21 levels were determined by quantitative ELISA. Cellular mitochondrial dysfunction was
assessed by COX (cytochrome c oxidase) histochemistry of lower limb skeletal muscle biopsy. Serum FGF-21 levels
were elevated in 66% of subjects. Levels correlated significantly with current CD4 lymphocyte count (p = 0.042) and
with total CD4 count gain since initiation of anti-retroviral therapy (p = 0.016), but not with the nature or duration
of past or current anti-retroviral treatment. There was no correlation between serum FGF-21 levels and severity of
the muscle mitochondrial (COX) defect.
Conclusions: Serum FGF-21 levels are a poor predictor of muscle mitochondrial dysfunction in contemporary
anti-retroviral treated patients. Serum FGF-21 levels are nevertheless commonly elevated, in association with the
degree of immune recovery, suggesting a non-mitochondrial metabolic disturbance with potential implications for
future comorbidity.
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Mitochondrial dysfunction is a well-described compli-
cation of anti-retroviral therapy [1-7]. It is most
strongly associated with several of the older nucleoside
analogue reverse transcriptase inhibitors (NRTIs): zi-
dovudine (AZT), stavudine (d4T), didanosine (ddI),
and zalcitabine (ddC). Although these drugs are no
longer in common usage in industrialised countries,
there are nevertheless large numbers of patients who
have had extensive prior exposure to these drugs, and
some remain in common usage in developing coun-
tries. We have recently demonstrated that patients
with previous exposure to these NRTIs may have* Correspondence: brendan.Payne@ncl.ac.uk
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reproduction in any medium, provided the orpersistent cellular mitochondrial COX (cytochrome c
oxidase) defects in skeletal muscle, consequent on an
NRTI-induced accumulation of somatic (acquired)
mitochondrial DNA (mtDNA) mutations [8].
Non-invasive measures of mitochondrial damage
would be very valuable in the HIV clinic, both for
the diagnosis of anti-retroviral associated mitochon-
drial dysfunction and the serial monitoring of such
patients. The determination of mtDNA content in
peripheral blood mononuclear cells (PBMCs) has
previously been proposed as such a measure [5,9-11].
This consideration arises from the fact that the
mitochondrially-toxic NRTIs (as listed above) cause a
reduction in cellular mtDNA content (depletion) dur-
ing therapy [2,3,6,10,12-16]. However, modern N(t)
RTIs such as tenofovir (TDF) and abacavir (ABC) do
not cause mtDNA depletion [17], and as a result,
mtDNA levels return to normal with a switch awaytd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mtDNA levels is not a useful measure of on-going
mitochondrial dysfunction due to an NRTI exposure in
the distant past.
In contrast, FGF-21 (fibroblast growth factor 21) has
recently been proposed as a valuable serum measure in
inherited mitochondrial disease [18]. In these patients,
serum FGF-21 levels showed a very strong correlation
with mitochondrial dysfunction on skeletal muscle bi-
opsy, as determined by the percentage of cells express-
ing a COX defect [18]. FGF-21 is thought to regulate
mitochondrial activity and enhance oxidative capacity,
mediated via PGC-1α (peroxisome proliferator-activated
receptor gamma co-activator 1-alpha) expression [19]. To
date, one study has assessed serum FGF-21 in HIV infec-
tion, and demonstrated elevated levels [20]. Given the re-
cently described association between serum FGF-21
elevation and muscle COX defects in inherited mitochon-
drial disorders [18], and the recent observation of signifi-
cant COX defects in long-term anti-retroviral treated
HIV-infected patients [8], we speculated that muscle mito-
chondrial dysfunction might also drive the FGF-21 eleva-
tion in anti-retroviral treated HIV infection.Patient characteristics
All subjects gave informed written consent for partici-
pation, and the study was approved by local research
ethics committee (Newcastle and North Tyneside
Research Ethics Committee). We performed a cross-
sectional study of adult HIV-1 infected patients, receiv-
ing ambulatory care at one of two specialist clinics in
Newcastle-upon-Tyne, UK. Patients with current active
hepatitis B or C co-infection, known inherited or non-
HIV-associated neuromuscular disease, and diabetes
mellitus were excluded. No subjects were clinically
obese (BMI >30). 32 HIV-infected subjects participated,
of whom 81% were male. 84% were of white Caucasian
ethnicity and the remainder black African. Mean age
was 48.7 years, with age range of 29–71 years. Mean
duration of diagnosed HIV infection was 10.8 years.
Mean current CD4 lymphocyte count was 663 cells/μl,
and 61% of subjects had nadir CD4 count of <200 cells/
μl. All subjects were currently receiving combination
anti-retroviral therapy, with a mean duration of treat-
ment of 9.2 years. 97% of patients had fully suppressed
HIV plasma viral load (<50 HIV-1 RNA copies/ml). 81%
of subjects were receiving a non-nucleoside reverse
transcriptase inhibitor (NNRTI) and 22% a ritonavir-
boosted protease inhibitor (PI). Regarding past (life-
time) NRTI treatment experience, 72% of patients had a
history of AZT exposure, and 25% had a history of prior
d-drug (dideoxynucleoside analogue) exposure. Charac-
teristics of individual subjects are shown in Table 1.FGF-21 determination
Serum FGF-21 levels were determined by quantitative
ELISA (BioVendor, Brno, Czech Republic), performed
in triplicate, and normalised by log10 transformation. A
serum FGF-21 level of <200 pg/ml was considered as
normal in keeping with recent data [18]. Statistical ana-
lyses were performed in SPSS 19, using student’s t-test
to compare binary variables and Pearson’s correlation
coefficient (r) to examine the relationship between log10
serum FGF-21 levels and continuous variables. Twenty-
one of 32 subjects (66%) had serum FGF-21 levels
greater than the normal range, with four being very
elevated (>800 pg/ml). On univariate analysis, serum
FGF-21 levels were positively correlated with current
CD4 lymphocyte count (r = 0.36, p = 0.042), but more
strongly correlated with total CD4 cell count gain since
initiation of anti-retroviral therapy (current minus
nadir) (r = 0.45, p = 0.016) (Figure 1). In addition,
plasma glucose levels correlated with serum FGF-21
levels, although this did not quite reach statistical sig-
nificance (r = 0.34, p = 0.06, Figure 2), whereas as serum
lipids and liver function did not. No other demographic
or treatment variables were significantly associated with
serum FGF-21 levels, including the nature of current or
prior anti-retroviral therapy (Table 2). FGF-21 levels did
not differ significantly between patients with or without
clinical lipodystrophy syndrome. Only CD4 lymphocyte
count gain was independently associated with serum
FGF-21 levels on multivariate linear regression analysis
(p = 0.016).
Skeletal muscle mitochondrial histochemistry
COX histochemistry was performed on cryo-sections
obtained from lower limb skeletal muscle biopsies on 31
of the 32 subjects (biopsy data for one subject was not
analysable). Results of 22 of these biopsies have been re-
ported in our previous work [8], whereas the remaining
9 have not. COX contains respiratory chain subunits
encoded by the mitochondrial genome, and fibres stain
brown (positive) in the presence of intact respiratory
chain activity (Figure 3). Proportional COX defect was
determined by counting ≥500 fibres per biopsy, and
normalised by log10 transformation. There was no cor-
relation between serum FGF-21 levels and percentage
COX defects on biopsy (r = −0.02, p = 0.9, Figure 4).
Discussion
We have shown that serum FGF-21 levels are frequently
elevated in contemporary anti-retroviral treated HIV-
infected patients, but do not correlate with the severity
of muscle mitochondrial (COX) defect. In contrast, a
previous study has shown a very strong correlation be-
tween these parameters in patients with inherited mito-
chondrial disorders [18]. Ours is the first study to
Table 1 Patient characteristics
Age (y) Gender Ethnicity Duration of
diagnosed HIV (mo)
ART
duration (mo)
Nadir CD4
count (cells/uL)
Current CD4
count (cells/uL)
LDS ART (current) ART (lifetime) COX
defect (%)
Serum FGF-21
(pg/mL)
71 M WB 130 130 UK 530 Y TDF FTC EFV ddi AZT 3TC EFV TDF FTC 3.0% 232
48 F BA 100 99 10 487 N TDF FTC NVP AZT 3TC EFVTDF FTC NVP 0.1% >1920
34 F WB 88 86 218 1121 Y ABC 3TC NVP AZT 3TC NVP ABC 0.0% 560
55 F BA 64 27 112 426 N TDF FTC AZT DRV/r TDF FTC LPV/r AZT DRV/r 0.8% 164
43 M BA 87 87 152 306 N TDF FTC EFV AZT 3TC EFV TDF FTC 0.8% 20
42 M WB 185 147 150 636 N AZT 3TC EFV AZT 3TC NVP 0.0% 342
63 M WB 97 97 169 870 N ABC 3TC EFV AZT 3TC EFV ABC 0.0% 204
29 M WB 84 32 197 401 N TDF FTC EFV TDF FTC EFV 0.0% 809
63 M WB 238 221 NA 438 N ABC 3TC NVP AZT ddl d4T 3TC ddC IDV NVP ABC 2.2% 440
62 M WB 63 62 56 190 N TDF FTC NVP TOP FTC NVP 0.2% 156
52 M WB 225 225 120 728 Y TDF FTC ATV/r AZT ddC ddl 3TC d4T SQV NVP
IDV NFV ABC TDF LPV/r FTC ATV/r
1.3% 328
36 M WB 139 138 197 627 N AZT 3TC EFV AZT 3TC EFV TDF FTC 0.3% 214
51 M WB 190 183 10 747 N ABC TDF NVP AZT ddl d4T 3TC RTV NVP
IDV ddC ABC ATV/r TDF
4.9% 252
33 F WB 96 95 83 1289 N TDF FTC EFV AZT 3TC EFV TDF FTC 0.0% 177
48 M WB 102 100 259 1329 Y AZT 3TC EFV AZT 3TC EFV 0.4% 409
51 M WB 145 144 151 421 N AZT 3TC NVP AZT 3TC NVP 1.4% 254
66 M WB 71 26 287 455 N TDF FTC EFV TDF FTC EFV 11.2% 470
46 M WB 158 157 250 1452 N TDF FTC EFV AZT 3TC IDV EFV ABC TDF FTC 1.4% 1218
61 M WB 116 113 NA 498 Y TDF FTC NVP AZT 3TC EFV NVP TDF FTC 2.4% 182-
30 M WB 88 23 283 661 N TDF FTC DRV/r TDF FTC EFV DRV/r 0.1% 207
62 M WB 284 202 NA 422 N ABC NVP LPV/r SQV AZT ddC 3TC d4T ddl
IDV ABC NVP NFV LPV/r
0.8% 92
45 WB 159 158 176 660 N TDF FTC NVP AZT 3TC IDV NVP TDF FTC 0.0% 60
54 M WB 79 38 244 638 N TDF FTC DRV/r TDF FTC EFV DRV/r 3.4% 178
52 M WB 166 164 0 662 Y TDF FTC NVP AZT d4T IDV NFV SQV 3TC
NVP ddl TDF FTC
2.8% 525
51 M WB 243 171 327 539 Y TDF FTC EFV AZT ddl RTV NFV TDF FTC EFV 1.5% 231
35 F BA 62 25 380 638 N TDF FTC EFV TOP FTC EFV 0.0% 82
53 M WB NA 48 301 804 N TDF FTC EFV TDF FTC EFV NA 490
36 M WB 130 130 18 898 N TDF FTC ATV/r AZT 3TC EFV TDF FTC ATV/r 0.0% 530
48 M WB 53 14 332 443 N TDF FTC EFV TDF FTC EFV 0.0% 56
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Table 1 Patient characteristics (Continued)
52 F BA 83 81 17 485 Y TDF FTC EFV AZT 3TC EFV TDF FTC 0.7% 224
38 M WB 129 128 4 761 Y TDF FTC EFV AZT 3TC EFV TDF FTC 0.0% 935
47 M WB 183 164 305 668 Y ABC RAL ATV/r d4T 3TC NVP ddl IDV ABC ATV/r RAL 9.8% 114
Summary characteristics of individual HIV-infected subjects. (WB, white British; BA, black African; ART, anti-retroviral therapy; LDS, lipodystrophy syndrome; AZT, zidovudine; d4T, stavudine; ddI, didanosine; ddC, zalcita-
bine; 3TC, lamivudine; ABC, abacavir; TDF, tenofovir; FTC, emtricitabine; EFV, efavirenz; NVP, nevirapine; ATV, atazanavir; DRV, darunavir; LPV, lopinavir; SQV, saquinavir; NFV, nelfinavir; IDV, indinavir; RTV, ritonavir at
therapeutic dose; /r, ritonavir at pharmacokinetic boosting dose; RAL, raltegravir; COX, cytochrome c oxidase; FGF-21, fibroblast growth factor 21; NA, not available).
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Figure 1 Correlation of serum FGF-21 levels with immune
reconstitution. Correlation of log10 serum FGF-21 (fibroblast
growth factor 21) levels in HIV-infected subjects and CD4
lymphocyte count gain on treatment (current minus nadir)
(r = 0.45, p = 0.016). (* Serum FGF-21 >1920 pg/ml, the upper limit
of quantitation of the assay).
Table 2 Associations of serum FGF-21 levels
(a)
Variable (n) Log10 Serum FGF-21,
mean (SD)
p
value
Gender Male (26) 2.39 (0.40)
Female (6) 2.46 (0.48) 0.71
Ethnicity Caucasian (27) 2.44 (0.33)
Black African
(5)
2.21 (0.72) 0.27
Current ART PI (7) 2.29 (0.26)
No PI (25) 2.43 (0.44) 0.43
Lifetime ART d-drugs (8) 2.38 (0.26)
No d-drugs (24) 2.41 (0.45) 0.86
AZT (23) 2.44 (0.42)
No AZT (9) 2.30 (0.39) 0.41
Lipodystrophy Yes (10) 2.50 (0.27)
No (22) 2.36 (0.46) 0.39
Lipid-lowering
therapy
Yes (8) 2.32 (0.52)
No (24) 2.43 (0.38) 0.53
(b)
Variable Correlation
coefficient (r)
p
value
Age −0.07 0.69
Duration of diagnosed
HIV infection
−0.08 0.67
Duration of
lifetime ART
Total 0.12 0.50
d-drug 0.01 0.97
AZT 0.13 0.47
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proven mitochondrial defects in HIV-infected patients.
What is the reason for this apparent discrepancy in
findings? Firstly, the prior study demonstrating serum
FGF-21 elevation in mitochondrial disease included a
large number of patients with childhood-onset disease.
Such patients typically have very severe muscle COX
defects (affecting up to ~60% of fibres). In contrast,Figure 2 Correlation of serum FGF-21 levels with plasma
glucose. Correlation of log10 serum FGF-21 (fibroblast growth
factor 21) levels in HIV-infected subjects and random plasma glu-
cose concentration (r = 0.34, p = 0.06). (* Serum FGF-21 >1920
pg/ml, the upper limit of quantitation of the assay).
CD4 lymphocyte
count
Nadir −0.29 0.14
Current 0.36 0.042
CD4 count gain (Current minus
nadir)
0.45 0.016
Serum ALT 0.27 0.14
Plasma glucose 0.34 0.06
Serum lipids Total
cholesterol
−0.03 0.87
HDL
cholesterol
0.02 0.90
Non-HDL
cholesterol
−0.06 0.75
Mitochondrial
histochemistry
COX defect
(log10)
−0.02 0.91
(a) binary variables; (b) continuous variables. (PI, protease inhibitor; AZT,
zidovudine; d-drug, dideoxynucleoside analogue; ART, anti-retroviral therapy;
ALT, alanine transaminase; HDL, high density lipoprotein).
Bold type indicates statistically significant associations.
Figure 3 COX histochemistry. Example of mitochondrial COX/SDH
(cytochrome c oxidase/succinate dehydrogenase) histochemistry on
lower limb skeletal muscle biopsy of an anti-retroviral treated
HIV-infected patient. Normal (COX positive) fibres stain brown,
whereas COX deficient fibres counterstain blue due to preserved
SDH activity.
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ders typically have more modest COX defects, compar-
able with those seen in our HIV-infected patients (up
to ~10% of fibres). The fact that some patients in our
study with a biopsy COX defect of >5% of fibres had
relatively normal FGF-21 levels suggests that this
serum measure is not particularly sensitive for mild to
moderate muscle mitochondrial defects. Secondly, the
markedly abnormal serum FGF-21 levels seen in some
patients with no significant COX defect suggest a non-
mitochondrial origin, as has been observed in otherFigure 4 Correlation of serum FGF-21 levels and mitochondrial
defects. Correlation of log10 serum FGF-21 (fibroblast growth factor
21) levels in HIV-infected subjects and percentage COX (cytochrome c
oxidase) defect on lower limb skeletal muscle biopsy (r = -0.02,
p = 0.9). (* Serum FGF-21 >1920 pg/ml, the upper limit of quantitation
of the assay).metabolic disorders [21-23]. In the only previous
study of FGF-21 levels in HIV infection, the authors
found associations of FGF-21 levels with obesity, gly-
caemia, dyslipidaemia and liver dysfunction, in line
with literature from HIV-uninfected patients [24]. In
our study, we specifically excluded diabetic and obese
subjects (as we wished to maximise the likelihood
of detecting any association with NRTI-induced mito-
chondrial dysfunction). Interestingly however, the
strongest predictor of serum FGF-21 levels seen in our
study was a novel association with total CD4 lympho-
cyte count gain. This is an intriguing finding. It
is plausible that patients who have low nadir CD4
lymphocyte counts may experience more profound
metabolic changes as they undergo immune reconsti-
tution on anti-retroviral therapy, switching from a
catabolic state to an excessively anabolic state associ-
ated with a ‘return to health’. This association with
CD4 count gain should be further explored by longitu-
dinal study.
In conclusion, serum FGF-21 levels do not appear
to be a sensitive or specific marker of muscle mito-
chondrial dysfunction in contemporary anti-retroviral
treated patients. Nevertheless they are commonly ele-
vated in association with immune recovery. As serum
FGF-21 levels in the HIV-uninfected population are
elevated in conditions associated with increased car-
diovascular risk, it is very plausible that serum FGF-21
elevation in anti-retroviral treated HIV infection may
also be a marker of an adverse metabolic risk in
this patient group. Given the known increase in cardio-
vascular disease in anti-retroviral treated patients [25],
the prognostic significance of our findings merits fur-
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